We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
TG Therapeutics (TGTX) Outpaces Stock Market Gains: What You Should Know
Read MoreHide Full Article
TG Therapeutics (TGTX - Free Report) closed at $19.34 in the latest trading session, marking a +1.79% move from the prior day. This change outpaced the S&P 500's 0.28% gain on the day. At the same time, the Dow added 0.11%, and the tech-heavy Nasdaq gained 3.77%.
Prior to today's trading, shares of the biopharmaceutical company had gained 47.52% over the past month. This has outpaced the Medical sector's loss of 1.38% and the S&P 500's gain of 3.54% in that time.
Investors will be hoping for strength from TG Therapeutics as it approaches its next earnings release. The company is expected to report EPS of -$0.26, up 62.86% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $0.04 million, down 98.28% from the prior-year quarter.
Any recent changes to analyst estimates for TG Therapeutics should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 3.14% lower. TG Therapeutics is holding a Zacks Rank of #3 (Hold) right now.
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 149, putting it in the bottom 41% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
TG Therapeutics (TGTX) Outpaces Stock Market Gains: What You Should Know
TG Therapeutics (TGTX - Free Report) closed at $19.34 in the latest trading session, marking a +1.79% move from the prior day. This change outpaced the S&P 500's 0.28% gain on the day. At the same time, the Dow added 0.11%, and the tech-heavy Nasdaq gained 3.77%.
Prior to today's trading, shares of the biopharmaceutical company had gained 47.52% over the past month. This has outpaced the Medical sector's loss of 1.38% and the S&P 500's gain of 3.54% in that time.
Investors will be hoping for strength from TG Therapeutics as it approaches its next earnings release. The company is expected to report EPS of -$0.26, up 62.86% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $0.04 million, down 98.28% from the prior-year quarter.
Any recent changes to analyst estimates for TG Therapeutics should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 3.14% lower. TG Therapeutics is holding a Zacks Rank of #3 (Hold) right now.
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 149, putting it in the bottom 41% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.